Cancer News: Cervical
Intensity-modulated radiation therapy (IMRT) causes less side effects in cervical and endometrial cancer than conventional radiotherapy (RT).
Weight influenced the survival time of overweight and underweight women with cervical cancer, a new study shows.
Cervical cancer patients had less bowel side effects when treated with image-guided intensity-modulated radiation therapy, a new study reveals.
Combining two forms of brachytherapy (a type of radiation therapy) against cervical cancer was shown to deliver higher dose without an increase in side-effects.
Bevacizumab (Avastin) has been recommended as a treatment for cervical cancer patients, expanding its current marketing authorization.
Cervical cancer that has spread elsewhere, or has recurred after treatment, shrunk more when doctors added an experimental drug to standard chemotherapy.
The US FDA has approved bevacizumab for intravenous infusion for treatment of persistent, recurrent or metastatic cervical cancer, combined with other drugs.
There are several things women can do to lower their risk of developing certain types of cancer and improve their chances for survival if they do develop one of them, according to the Society of Gynecologic Oncology (SGO).
Food such as corn tortilla, rice, chili pepper, processed sauces, chicken breast and eggs, are related with cervical and liver cancer in humans, according to scientists.
ZedScan, a device for diagnosing cervical cancer, has received EC certification allowing its use in the European Union.
A new study attempts to explain why some young women at high risk for cervical cancer do not get the HPV vaccine.
Few children and young adults with autoimmune diseases receive the HPV vaccination, despite studies showing the vaccine to be safe and effective.
Social barriers (including housing and income) cause delays in cancer screening follow-up for some women, according to a recent study.
Screening for the human papillomavirus (HPV) is more effective than Pap tests for protecting women against invasive cervical cancer, a new study suggests.
Primary HPV screening provides 60–70% greater protection against invasive cervical cancer than cytology-based screening
Primary screening for HPV (Human Papilloma Virus) provides 60–70% greater protection against invasive cervical cancer than the cytology-based (‘smear-test’) screening currently used in most countries where cervical screening is available, according to new results published in The Lancet.
A single dose of human papillomavirus vaccine (HPV) achieved stable antibody levels at 48 months, suggesting that one dose of vaccine might afford adequate protection, according to a study from Central America.
Many criteria affect HPV screening rates among low-risk women. The most important may be whether their doctor is male or female.
An Internet-based intervention may significantly improve both sexual function and satisfaction in women with sexual dysfunction years after treatment for breast or gynecologic cancer, according to a randomized trial reported in the November issue of the Journal of the National Comprehensive Cancer Network. Leslie R. Schover, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues also found that the intervention may reduce emotional distress and improve the overall quality of life in these women after treatment.
Barriers to human papillomavirus (HPV) vaccination among adolescents in the U.S. range from financial concerns and parental attitudes to social influences and concerns about the vaccination's effect on sexual behavior, according to a review of the available medical literature published by JAMA Pediatrics, a JAMA Network publication.
Women who've had a hysterectomy, and most women over 65, don't need regular swabs for signs of cervical cancer - but lots of them are getting the test anyway, say U.S. researchers.
HPV self-testing is as effective as tests done by doctors, according to a Lund University study. Simple HPV home tests could therefore complement existing screening programs, and identify more women at risk for cervical cancer.
Researchers from 3 countries have completed a genomic analysis of cervical cancer, including at least one genetic mutation for which targeted treatments have been approved for other forms of cancer.
Getting the HPV vaccine after the age of 18 leads to similar outcomes with no vaccination at all, according to investigators.
Cervical cancer diagnosis and stage indication via a blood-based test has been demonstrated, which can help in prompt treatment.
Researchers analyzed the structure of a cervical cancer related protein (called E6AP) in high detail.
Women over 50 not screened for cervical cancer have 6 times the risk to be diagnosed in later life.
Latest research on cervical cancer identified a gene as a potential target to stop the tumor's growth. This development may improve future treatment options.
In a localized trial, a large portion of women with HPV-positive early stage cervical cancer returned to normal after being treated with the HIV drug lopinavir.
Combining chemotherapy with bevacizumab (also known as Avastin) extended survival in patients with advanced cervical cancer who participated in a phase 3 trial.
The protection against cervical abnormalities, including cancer, offered by the HPV vaccine was further confirmed by a new research conducted in Australia.